Análise das ações da Lazard questiona metas de crescimento apesar do dividend yield

Uma análise de investimento destaca preocupações sobre a posição competitiva e as perspectivas de receita da Lazard.

O relatório observa que a Lazard carece de um diferencial competitivo duradouro em bancos de investimento ou gestão de ativos. O documento aponta para o negócio altamente cíclico da empresa, com quedas recentes nas receitas atreladas à atividade do mercado de capitais. A companhia estabeleceu uma meta de dobrar suas receitas anuais até 2030, mas a análise questiona se o histórico de crescimento moderado e o fraco ímpeto operacional sustentam esse objetivo. Apesar de um dividend yield de 4,3%, a recomendação é manter as ações devido às perspectivas limitadas de crescimento e a um prêmio de avaliação em relação ao setor.

Artigos relacionados

NewLake Capital Partners maintains a strong buy rating with a nearly 12 percent dividend yield.

Reportado por IA

BNP Paribas analyst Kumar Rakesh has cautioned investors against viewing largecap Indian IT stocks as a straightforward value play. He points to weak FY27 guidance, AI-led disruptions, and stalled client spending as major challenges. Buybacks and dividends offer some support, but earnings risks remain high.

HCL Technologies shares dropped more than 9% following disappointing March quarter results and cautious FY27 guidance. While year-on-year profit and revenue grew, sequential declines in constant currency and margins fell short of expectations. Brokerages including JPMorgan and HSBC cut their target prices in response.

Reportado por IA

Allianz SE delivered a strong start to 2026 during its first quarter earnings call on May 13. Chief Financial Officer Claire-Marie Coste-Lepoutre highlighted continued progress across key strategic areas. The company reaffirmed its full year outlook despite elevated market volatility.

An analyst has named Aris Mining (NYSE:ARIS) as the top pick in the gold sector, projecting significant production growth and financial gains. The company aims to quadruple output by 2031, with EBITDA expected to triple by 2027 under high gold price assumptions. The stock carries a price target of $38 for 2027, suggesting over 100% upside.

Reportado por IA

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

quarta-feira, 24 de junho de 2026, 20:11h

JPMorgan turns cautious on Indian IT growth outlook

quarta-feira, 24 de junho de 2026, 01:25h

Largecaps lead profit growth in March 2026 quarter

terça-feira, 02 de junho de 2026, 00:26h

Kayne Anderson BDC rated hold amid portfolio concerns

domingo, 31 de maio de 2026, 16:54h

Draganfly stock faces sell rating amid growth concerns

sexta-feira, 22 de maio de 2026, 07:17h

OneMain Holdings stock gets strong buy upgrade

sábado, 16 de maio de 2026, 10:41h

Mid-America Apartment Communities stock rated hold amid expense pressures

terça-feira, 05 de maio de 2026, 18:58h

Analyst downgrades Home Depot stock to hold amid headwinds

sexta-feira, 01 de maio de 2026, 18:02h

Seeking Alpha releases top 25 high-growth dividend stocks for May 2026

quinta-feira, 30 de abril de 2026, 20:32h

Lanvin Group revenues drop 18% in fiscal 2025

quarta-feira, 22 de abril de 2026, 16:12h

L’Oréal’s Q1 2026 revenues rise 7.6% to €12.2 billion

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar